TAFAMIDIS MEGLUMINE

Search structure
Trade Names:
Synonyms:
Status: Approved (2019)
Entry Type: Small molecule
Molecule Category: UNKNOWN
UNII: ZU7CF08A1A

Structure
InChI Key DQJDBUPLRMRBAB-WZTVWXICSA-N
Smile CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.O=C(O)c1ccc2nc(-c3cc(Cl)cc(Cl)c3)oc2c1
InChI
InChI=1S/C14H7Cl2NO3.C7H17NO5/c15-9-3-8(4-10(16)6-9)13-17-11-2-1-7(14(18)19)5-12(11)20-13;1-8-2-4(10)6(12)7(13)5(11)3-9/h1-6H,(H,18,19);4-13H,2-3H2,1H3/t;4-,5+,6+,7+/m.0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C21H24Cl2N2O8
Molecular Weight 503.34
AlogP 4.5
Hydrogen Bond Acceptor 3.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 2.0
Polar Surface Area 63.33
Molecular species ACID
Aromatic Rings 3.0
Heavy Atoms 20.0

Pharmacology

Action Mechanism of Action Reference
STABILISER Transthyretin stabiliser PubMed

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Cardiomyopathies 4 D009202 ClinicalTrials
Amyloidosis 4 D000686 FDA
Amyloidosis, Familial 4 D028226 FDA
Amyloid Neuropathies, Familial 2 D028227 ClinicalTrials
Polyneuropathies 2 D011115 ClinicalTrials

Related Entries

MCS

Scaffolds

Adverse Reactions

SOC By Demographic Distribution
System Organ Classification (SOC)
Relative Frequency (%)
General disorders and administration site conditions
20.95
Cardiac disorders
14.86
Nervous system disorders
11.49
Gastrointestinal disorders
8.11
Injury, poisoning and procedural complications
6.76
Psychiatric disorders
6.76
Respiratory, thoracic and mediastinal disorders
6.08
Metabolism and nutrition disorders
4.73
Vascular disorders
4.73
Eye disorders
2.03
Immune system disorders
2.03
Investigations
2.03
Skin and subcutaneous tissue disorders
2.03

Cross References

Resources Reference
ChEBI 79345
ChEMBL CHEMBL2105675
FDA SRS ZU7CF08A1A
PubChem 24970412
SureChEMBL SCHEMBL14783506
CONTENTS